Reports Q1 revenue $168.04M, consensus $170.9M. “Our business is off to a solid start in 2025 with our team delivering a record number of results to patients in the first quarter and improving our adjusted EBITDA by over 100% from prior year,” said Tony Zook, CEO of NeoGenomics (NEO). “We expect to continue to accelerate growth as we expand our portfolio with upcoming product launches, win on customer experience and capitalize on our world-class sales force, supporting our mission to improve patient care.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NEO Upcoming Earnings Report: What to Expect?
- NeoGenomics price target lowered to $12 from $16 at BofA
- NeoGenomics Poised for Long-Term Growth: Buy Rating Affirmed Amid Strategic Leadership and Growth Strategy
- NeoGenomics completes acquisition of Pathline
- NeoGenomics CEO Chris Smith to depart, Tony Zook to succeed